Sherry Niessen

Mirati Therapeutics (United States) — United States

Medicine · Health Sciences

52h-index9.2kcitations104works13.52yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Peptidase Inhibition and Analysis(14), Advanced Proteomics Techniques and Applications(13), Click Chemistry and Applications(13), Microtubule and mitosis dynamics(10), Chemical Synthesis and Analysis(9)

Publications104 total

Abstract 4295: Discovery of a novel class of androgen-competitive AR inhibitors that can combat drug resistance due to AR gene amplification
Cancer Research·2025
An allosteric cyclin E-CDK2 site mapped by paralog hopping with covalent probes
Nature Chemical Biology·2024· 15 citedOpen Access
Photoaffinity labelling with small molecules
Nature Reviews Methods Primers·2024· 32 cited
Expanding the ligandable proteome by paralog hopping with covalent probes
2024· 7 citedOpen Access
Rapid adaptation to CDK2 inhibition exposes intrinsic cell-cycle plasticity
Cell·2023· 158 cited
Abstract 5992: Cells rapidly adapt to CDK2 inhibitors via plasticity of the CDK2/4/6-Rb-E2F axis
Cancer Research·2023· 2 cited
Proteomic Profiling of Intra-Islet Features Reveals Substructure-Specific Protein Signatures
Molecular & Cellular Proteomics·2022· 10 citedOpen Access
PARP1-SNAI2 transcription axis drives resistance to PARP inhibitor, Talazoparib
Scientific Reports·2022· 13 citedOpen Access
Reversible lysine-targeted probes reveal residence time-based kinase selectivity
Nature Chemical Biology·2022· 99 citedOpen Access
Expanding control of the tumor cell cycle with a CDK2/4/6 inhibitor
Cancer Cell·2021· 172 cited
CCDC 2099722: Experimental Crystal Structure Determination
The Cambridge Structural Database·2021Open Access
Abstract 330: Engineering electrophile-sensitive kinase mutants to accelerate oncology target validation
Cancer Research·2021
Abstract 1954: Identifying synthetic lethality with novel CDK2 small molecule inhibitors via integration of high-content microscopy and -omics level platforms
Cancer Research·2021
Discovery of PF-06873600, a CDK2/4/6 Inhibitor for the Treatment of Cancer
Journal of Medicinal Chemistry·2021· 112 citedOpen Access
Dissecting the molecular determinants of clinical PARP1 inhibitor selectivity for tankyrase1
Journal of Biological Chemistry·2020· 76 citedOpen Access
The intramembrane protease Sppl2a is required for B cell and DC development and survival via cleavage of the invariant chain
UNC Libraries·2020Open Access
Chemoproteomic Discovery of AADACL1 as a Regulator of Human Platelet Activation
UNC Libraries·2020Open Access
Mps1 Phosphorylation of Dam1 Couples Kinetochores to Microtubule Plus Ends at Metaphase
UNC Libraries·2020Open Access
The yeast lgl family member Sro7p is an effector of the secretory Rab GTPase Sec4p
UNC Libraries·2020Open Access
Symmetric Arginine Dimethylation Is Selectively Required for mRNA Splicing and the Initiation of Type I and Type III Interferon Signaling
Cell Reports·2020· 42 citedOpen Access
page 1 of 6Next →

Frequent Co-authors

Benjamin F. Cravatt(21), John R. Yates(14), Heather Hoover(11), John C. Kath(6), Rose Ann Ferre(5), Douglas C. Behenna(5), Khanh Tran(5), Marc Montminy(4), Karen Oegema(4), Arshad Desai(4), Chu Wang(4), Farnusch Kaschani(4), Renier A. L. van der Hoorn(4), John D. Lapek(4), Scott L. Weinrich(4), Asako Nagata(4), Martha A. Ornelas(4), Brion W. Murray(4), K.S. Gajiwala(4), Daniel K. Nomura(3)